Efavirenz

依非韦伦

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameEfavirenz
Drug Alias Name依法韦仑Efavirenzum依非韦仑依氟维纶Stocrin +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitors
TargetsHuman immunodeficiency virus type 1 reverse transcriptase
Therapy Area/IndicationsSolid tumoursAlzheimer DiseaseHepatic Insufficiency +[9] 
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date1998/09/17
Country/TerritoryCanadaUnited StatesPoland +[20] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesXuanwu Hospital Of Capital Medical UniversityCase Western Reserve UniversityMerck Sharp & Dohme Corp +[4] 
Inactive CompaniesAbbott LaboratoriesBristol Myers Squibb SrlcompanyInstitut Bergonié +[11] 
Active IndicationsAlzheimer DiseaseHIV InfectionsCreutzfeldt-Jakob Syndrome
Inactive IndicationsSolid tumoursHepatic InsufficiencyProstatic Neoplasms +[6] 

Other Information

ATC CodeJ05AG03
Related LinksWikipediaDrugBankKEGG